Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2)

https://doi.org/10.1016/j.bmcl.2007.12.031Get rights and content

Abstract

We report herein the initial exploration of novel selective HDAC1/HDAC2 inhibitors (SHI-1:2). Optimized SHI-1:2 structures exhibit enhanced intrinsic activity against HDAC1 and HDAC2, and are greater than 100-fold selective versus other HDACs, including HDAC3. Based on the SAR of these agents and our current understanding of the HDAC active site, we postulate that the SHI-1:2 extend the existing HDAC inhibitor pharmacophore to include an internal binding domain.

References and notes (21)

  • C.M. Grozinger et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (1999)
    W. Fischle et al.

    J. Biol. Chem.

    (2001)
  • M.J. Peart et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (2005)
  • P.T. Meinke et al.

    Curr. Med. Chem.

    (2001)
  • For cell viability assay procedure, see Ref....
  • A.H. Lund et al.

    Genes Dev.

    (2004)
  • J.E. Bolden et al.

    Nat. Rev. Drug Discov.

    (2006)
  • G. Blander et al.

    Annu. Rev. Biochem.

    (2004)
  • T.A. Miller et al.

    J. Med. Chem.

    (2003)
  • V.M. Richon

    Br. J. Cancer

    (2006)
    O.A.. O’Connor

    Br. J. Cancer

    (2006)
    M. Duvic et al.

    Br. J. Cancer

    (2006)
    P.A. Marks et al.

    Nat. Biotechnol.

    (2007)
  • T. Suzuki et al.

    J. Med. Chem.

    (1999)
    J. Kell

    Curr. Opin. Invest. Drugs

    (2007)
There are more references available in the full text version of this article.

Cited by (0)

†

Present address: Department of Medicinal Chemistry, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA.

View full text
Copyright © 2008 Elsevier Ltd. All rights reserved.